Abstract
The possible role of PGs and NO in the development of S of DBA/2J mice was investigated by evaluating the effects of dexamethasone, indometacin, mifepristone plus dexamethasone on the S, as well as of L-NAME both on the S in the electrocorticogram of DBA/2J mice and on morphine- and deltorphin II-induced EEG seizure in rabbits. The results of our data indicate that: a) Both dexamethasone and indometacin (1,10,100 μg/kg/i.p.) reduced the S of DBA/2J mice and mifepristone, a glucocorticoid receptor antagonist (1,10,100 μg/kg/i.p.), totally blocked the steroid effect b) L-NAME (3 – 300 μg/mouse/ i.c.v.) dose-dependently reduced the S of DBA/2J mice whereas DNAME at the same doses did not affect S of mice. The inhibitory effect of L-NAME on S of mice was dose-dependently reversed by L-arginine (L-ARG, 3 – 300 μg/mouse/ i.c.v.) but not by D-arginine. Finally, GTN its own (3 – 300 μg/mouse/ i.c.v.) significantly increased the S of mice and it was also able to reverse the inhibition on S of mice operated by L-NAME. c) Morphine and deltorphin II (100 μg/icv/toto) produce EEG seizure activity in rabbits and L-NAME (300 μg/i.c.v./toto), injected 15 min before morphine or deltorphin II, dose dependently prevented the EEG ictal episodes, the spiking activity and the synchronized EEG pattern induced by morphine or deltorphin II. The inhibitory effect of L-NAME on morphine or deltorphin II seizures was dose-dependently reversed by L-arginine (300 μg/icv/toto) but not by D-arginine. Finally, GTN on its own (300 μg/icv/toto) significantly increased morphine or deltorphin II seizures in the rabbit and it was also able to reverse the inhibition on morphine or deltorphin II seizures operated by L-NAME. These results provide a strong evidence that both PGs and NO may play a significant role in the development of brain excitability.
Keywords: Prostaglandins, Nitric Oxide, Brain Excitability, dexamethasone, indometacin, electrocorticogram, glucocorticoid, receptor, antagonist, steroid
Current Medicinal Chemistry
Title: The Involvement of Prostaglandins and Nitric Oxide in the Development of Brain Excitability: A Relationship Study
Volume: 15 Issue: 24
Author(s): Anna Capasso
Affiliation:
Keywords: Prostaglandins, Nitric Oxide, Brain Excitability, dexamethasone, indometacin, electrocorticogram, glucocorticoid, receptor, antagonist, steroid
Abstract: The possible role of PGs and NO in the development of S of DBA/2J mice was investigated by evaluating the effects of dexamethasone, indometacin, mifepristone plus dexamethasone on the S, as well as of L-NAME both on the S in the electrocorticogram of DBA/2J mice and on morphine- and deltorphin II-induced EEG seizure in rabbits. The results of our data indicate that: a) Both dexamethasone and indometacin (1,10,100 μg/kg/i.p.) reduced the S of DBA/2J mice and mifepristone, a glucocorticoid receptor antagonist (1,10,100 μg/kg/i.p.), totally blocked the steroid effect b) L-NAME (3 – 300 μg/mouse/ i.c.v.) dose-dependently reduced the S of DBA/2J mice whereas DNAME at the same doses did not affect S of mice. The inhibitory effect of L-NAME on S of mice was dose-dependently reversed by L-arginine (L-ARG, 3 – 300 μg/mouse/ i.c.v.) but not by D-arginine. Finally, GTN its own (3 – 300 μg/mouse/ i.c.v.) significantly increased the S of mice and it was also able to reverse the inhibition on S of mice operated by L-NAME. c) Morphine and deltorphin II (100 μg/icv/toto) produce EEG seizure activity in rabbits and L-NAME (300 μg/i.c.v./toto), injected 15 min before morphine or deltorphin II, dose dependently prevented the EEG ictal episodes, the spiking activity and the synchronized EEG pattern induced by morphine or deltorphin II. The inhibitory effect of L-NAME on morphine or deltorphin II seizures was dose-dependently reversed by L-arginine (300 μg/icv/toto) but not by D-arginine. Finally, GTN on its own (300 μg/icv/toto) significantly increased morphine or deltorphin II seizures in the rabbit and it was also able to reverse the inhibition on morphine or deltorphin II seizures operated by L-NAME. These results provide a strong evidence that both PGs and NO may play a significant role in the development of brain excitability.
Export Options
About this article
Cite this article as:
Capasso Anna, The Involvement of Prostaglandins and Nitric Oxide in the Development of Brain Excitability: A Relationship Study, Current Medicinal Chemistry 2008; 15 (24) . https://dx.doi.org/10.2174/092986708785909076
DOI https://dx.doi.org/10.2174/092986708785909076 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Is VEGF a Key Target of Cotinine and Other Potential Therapies Against Alzheimer Disease?
Current Alzheimer Research Consequences of Iron Accumulation in Microglia and its Implications in Neuropathological Conditions
CNS & Neurological Disorders - Drug Targets Genetics and Genomics of Hepatic Acute Phase Reactants: A Mini-Review
Inflammation & Allergy - Drug Targets (Discontinued) Systemic Redox Biomarkers in Neurodegenerative Diseases
Current Drug Metabolism New Therapeutic Strategies in Perinatal Stroke
Current Drug Targets - CNS & Neurological Disorders Antioxidants as a Preventive Treatment for Epileptic Process: A Review of the Current Status
Current Neuropharmacology Closed-loop Neuropharmacology for Epilepsy: Distant Dream or Future Reality?
Current Neuropharmacology Video Game Addiction: Past, Present and Future
Current Psychiatry Reviews Progress and Outlooks in a Genetic Absence Epilepsy Model (WAG/Rij)
Current Medicinal Chemistry The Development of Medications for Alcohol-Use Disorders Targeting the GABAB Receptor System
Recent Patents on CNS Drug Discovery (Discontinued) Geriatric Psychopharmacology in Acute Settings
Current Psychopharmacology TRP Channels as Novel Targets for Endogenous Ligands: Focus on Endocannabinoids and Nociceptive Signalling
Current Neuropharmacology Borna Disease Virus (BDV): Neuropharmacological Effects of a CNS Viral Infection
Current Neuropharmacology Molecular Mechanisms Underlying Specificity of Excitotoxic Signaling in Neurons
Current Molecular Medicine Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) The Enigmatic Drug Binding Site for Sodium Channel Inhibitors
Current Molecular Pharmacology Cefepime-Induced Neurotoxicity
Central Nervous System Agents in Medicinal Chemistry Cross-Cultural Comparison of Mild Cognitive Impairment between China and USA
Current Alzheimer Research Voltage-Gated Sodium Channel Blockers for the Treatment of Chronic Pain
Current Topics in Medicinal Chemistry The Potential Clinical Properties of Magnesium
Current Medicinal Chemistry